Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 3;17(4):1223-1234.
doi: 10.1080/21645515.2020.1804245. Epub 2020 Oct 29.

Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1

Annika Skansberg  1 , Molly Sauer  1   2 , Marissa Tan  1 , Mathuram Santosham  1   2 , Mary Carol Jennings  1   2
Affiliations
Review

Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1

Annika Skansberg et al. Hum Vaccin Immunother. .

Abstract

Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually. Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure - ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam. In this review, we summarize the available clinical trial and post-introduction evidence for these three new orally administered rotavirus vaccines. All three vaccines have demonstrated safety and efficacy against rotavirus diarrhea, although publicly available preclinical data are limited in some cases. This expanding product landscape presents a range of options to optimize immunization programs, and new presentations of each vaccine are currently under development.

Keywords: Rotavirus; diarrhea; vaccines.

PubMed Disclaimer

References

    1. World Health Organization . Number of deaths by region, Diarrhoeal diseases. World Health Organization Global Health Observatory. [Accessed March9, 2020]. http://apps.who.int/gho/data/view.main.CM1002015REG6-CH3?lang=en.
    1. Global Burden of Disease Collaborative Network . Global burden of disease study 2017 (GBD 2017) results. [Accessed February 14, 2020]. http://ghdx.healthdata.org/gbd-results-tool.
    1. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD.. World health organization–coordinated global rotavirus surveillance network. Global, regional, and national estimates of rotavirus mortality in children <5 Years of Age, 2000-2013. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62(Suppl 2):S96–S105. doi:10.1093/cid/civ1013. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention . Rotavirus. centers for disease control and prevention. [Published September25, 2019; accessed February23, 2020]. https://www.cdc.gov/vaccines/pubs/pinkbook/rota.html.
    1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet Lond Engl. 2013;382(9888):209–22. doi:10.1016/S0140-6736(13)60844-2. - DOI - PubMed